Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Journal: Science translational medicine
Published: May 27, 2026
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Journal: Leukemia
Published: May 09, 2026
Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study.
Journal: Research square
Published: April 27, 2026
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.
Journal: Expert opinion on investigational drugs
Published: April 23, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Journal: Expert opinion on biological therapy
Published: March 17, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Journal: Nature medicine
Published: March 13, 2026
Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 30, 2025
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.
Journal: Journal for immunotherapy of cancer
Published: December 12, 2025
eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.
Journal: Journal of the American Society of Nephrology : JASN
Published: November 20, 2025
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.
Journal: Blood cancer journal
Published: November 04, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Journal: Expert opinion on emerging drugs
Published: October 30, 2025
Last Updated: 09/26/2026